A Case of Oropharyngeal Squamous Cell Carcinoma who Developed Sigmoid Colon Perforation after Cetuximab Treatment

• Hamasaki Sawako

  Graduate School of Medicine, Chiba University

• Kunii Naoki

  Graduate School of Medicine, Chiba University

• Makita Yuji

  Graduate School of Medicine, Chiba University

• Arimoto Shohei

  Graduate School of Medicine, Chiba University

• Kitani Rei

  Graduate School of Medicine, Chiba University

• Suzuki Takeshi

  Graduate School of Medicine, Chiba University

• Yamasaki Kazuki

  Graduate School of Medicine, Chiba University

• Yonekura Syuji

  Graduate School of Medicine, Chiba University

• Chazono Hideaki

  Graduate School of Medicine, Chiba University

• Sakurai Daiju

  Graduate School of Medicine, Chiba University

• Hanazawa Toyoyuki

  Graduate School of Medicine, Chiba University

• Okamoto Yoshitaka

  Graduate School of Medicine, Chiba University

Bibliographic Information

Other Title

• 中咽頭扁平上皮癌に対するセツキシマブ併用放射線治療後に発症した腸管穿孔例
• 臨床 中咽頭扁平上皮癌に対するセツキシマブ併用放射線治療後に発症した腸管穿孔例
• リンショウ チュウ イントウ ヘンペイ ジョウヒ ガン ニ タイスル セツキシマブ ヘイヨウ ホウシャセン チリョウ ゴ ニ ハッショウ シタ チョウカン センコウレイ

Abstract

A 73-year-old male was referred to our hospital complaining of swelling of his right neck, and was diagnosed as having oropharyngeal squamous cell carcinoma, clinical stage T2N2bM0. He had received concurrent radiotherapy with cetuximab treatment and achieved complete remission by the time he had received a total of 70 Gy of radiation to the neck and 7 courses of intravenous cetuximab treatment. However, he developed perforation of the sigmoid colon 1 month after completion of the cetuximab treatment. Cetuximab is a monoclonal antibody directed against epidermal growth factor receptor (EGFR), which binds to EGFR and inhibits cell proliferation. We searched PubMed and the Japan Medical Abstracts Society for cases of bowel perforation associated with cetuximab treatment, and identified 3 other cases of bowel perforation. All developed bowel perforation a couple of months after the completion of cetuximab treatment and had a history of gastrointestinal diseases like colon cancer, stoma creation and colonic diverticular disease. Only a few cases of severe gastrointestinal complications related to cetuximab treatment for head and neck cancer have been reported until now, and this is the first case of a patient with oropharyngeal carcinoma developing bowel perforation requiring urgent surgery. However, we suspect that EGFR inhibitors could exert toxic effects on the bowel mucosa in the same way as VEGF receptor inhibitors, the toxicity of which to the bowel mucosa came to be widely recognized during the post-marketing surveillance. Close observation with an index of suspicion for bowel perforation is thought to be necessary when treating head and neck cancer patients with cetuximab, especially in patients with a history of gastrointestinal diseases like diverticular disease.

Journal

• Practica Oto-Rhino-Laryngologica

  Practica Oto-Rhino-Laryngologica 109 (11), 803-808, 2016

  The Society of Practical Otolaryngology

Keywords

• oropharyngeal squamous cell carcinoma
• colon perforation
• cetuximab

Details

• CRID: 1390001204271829888
• NII Article ID: 130005268091
• NII Book ID: AN00107089
• DOI: 10.5631/jibirin.109.803
• ISSN: 18844545
• ISSN: 00326313
• NDL BIB ID: 027724259
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I027724259
• Web Site: https://www.jstage.jst.go.jp/article/jibirin/109/11/109_803/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2017175397
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed